Ernexa Therapeutics (ERNAW) Long-Term Deferred Tax (2012 - 2020)

Ernexa Therapeutics has reported Long-Term Deferred Tax for 4 years, with the latest figure at $34000.0 in Q4 2020.

• For the quarter ending Q4 2020, Long-Term Deferred Tax rose 88.89% year-over-year to $34000.0; the trailing twelve-month figure through Dec 2020 stood at $34000.0 (up 88.89% YoY), and the FY2020 full-year result was $34000.0, up 88.89% from the prior year.
• Long-Term Deferred Tax for Q4 2020 stood at $34000.0, up from $18000.0 in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $34000.0 in Q4 2020, with the low at $18000.0 in Q4 2019.
• Historically, Long-Term Deferred Tax has averaged $25000.0 across 3 years, with a median of $23000.0 in 2018.
• Annual changes were most pronounced in 2019 — Long-Term Deferred Tax declined 21.74% — and 2020, when it soared 88.89%.
• Ernexa Therapeutics' Long-Term Deferred Tax stood at $23000.0 in 2018, then fell by 21.74% to $18000.0 in 2019, then soared by 88.89% to $34000.0 in 2020.
• The last three Long-Term Deferred Tax figures came in at $34000.0 (Q4 2020), $18000.0 (Q4 2019), and $23000.0 (Q4 2018), per Business Quant data.